{"url_path":"/sec/nnvc/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1379006/0001104659-26-061499-index.html","accession_number":"0001104659-26-061499","cik":"0001379006","ticker":"NNVC","issuer_name":"NANOVIRICIDES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1379006/0001104659-26-061499-index.html","primary_entity_key":"0001379006","primary_entity_name":"NANOVIRICIDES, INC."},"word_count":631,"has_tables":true,"body_markdown":"NANOVIRICIDES, INC._March 31, 2026\n\nP5Y6M0001379006--06-302026Q3falsetruefalse0001379006us-gaap:RetainedEarningsMember2026-03-310001379006us-gaap:AdditionalPaidInCapitalMember2026-03-310001379006us-gaap:RetainedEarningsMember2025-12-310001379006us-gaap:AdditionalPaidInCapitalMember2025-12-3100013790062025-12-310001379006us-gaap:RetainedEarningsMember2025-09-300001379006us-gaap:AdditionalPaidInCapitalMember2025-09-3000013790062025-09-300001379006us-gaap:RetainedEarningsMember2025-06-300001379006us-gaap:AdditionalPaidInCapitalMember2025-06-300001379006us-gaap:RetainedEarningsMember2025-03-310001379006us-gaap:AdditionalPaidInCapitalMember2025-03-310001379006us-gaap:RetainedEarningsMember2024-12-310001379006us-gaap:AdditionalPaidInCapitalMember2024-12-3100013790062024-12-310001379006us-gaap:RetainedEarningsMember2024-09-300001379006us-gaap:AdditionalPaidInCapitalMember2024-09-3000013790062024-09-300001379006us-gaap:RetainedEarningsMember2024-06-300001379006us-gaap:AdditionalPaidInCapitalMember2024-06-300001379006us-gaap:CommonStockMember2026-03-310001379006nnvc:SeriesAConvertiblePreferredStockMember2026-03-310001379006us-gaap:CommonStockMember2025-12-310001379006nnvc:SeriesAConvertiblePreferredStockMember2025-12-310001379006us-gaap:CommonStockMember2025-09-300001379006nnvc:SeriesAConvertiblePreferredStockMember2025-09-300001379006us-gaap:CommonStockMember2025-06-300001379006nnvc:SeriesAConvertiblePreferredStockMember2025-06-300001379006us-gaap:CommonStockMember2025-03-310001379006nnvc:SeriesAConvertiblePreferredStockMember2025-03-310001379006us-gaap:CommonStockMember2024-12-310001379006nnvc:SeriesAConvertiblePreferredStockMember2024-12-310001379006us-gaap:CommonStockMember2024-09-300001379006nnvc:SeriesAConvertiblePreferredStockMember2024-09-300001379006us-gaap:CommonStockMember2024-06-300001379006nnvc:SeriesAConvertiblePreferredStockMember2024-06-300001379006nnvc:AtmOfferingMember2026-03-310001379006nnvc:StockWarrantsMember2024-07-012025-06-300001379006nnvc:StockWarrantsMember2026-03-310001379006nnvc:StockWarrantsMember2025-06-300001379006nnvc:ScientificAdvisoryBoardMember2025-07-012026-03-310001379006nnvc:RegisteredDirectOfferingMember2025-11-112025-11-110001379006nnvc:AtmOfferingMember2024-04-152024-04-150001379006nnvc:TheracourPharmaIncMemberus-gaap:RelatedPartyMember2026-01-012026-03-310001379006nnvc:TheracourPharmaIncMemberus-gaap:RelatedPartyMember2025-01-012025-03-310001379006nnvc:TheracourPharmaIncMemberus-gaap:RelatedPartyMember2025-07-012026-03-310001379006nnvc:TheracourPharmaIncMemberus-gaap:RelatedPartyMember2024-07-012025-03-310001379006nnvc:Dr.AnilDiwanMemberus-gaap:LineOfCreditMember2025-07-012026-03-310001379006nnvc:SeriesAConvertiblePreferredStockMember2026-03-310001379006nnvc:SeriesAConvertiblePreferredStockMember2025-06-300001379006nnvc:AtmOfferingMember2025-07-012026-03-310001379006us-gaap:RetainedEarningsMember2026-01-012026-03-310001379006us-gaap:RetainedEarningsMember2025-10-012025-12-310001379006us-gaap:RetainedEarningsMember2025-07-012025-09-300001379006us-gaap:RetainedEarningsMember2025-01-012025-03-310001379006us-gaap:RetainedEarningsMember2024-10-012024-12-310001379006us-gaap:RetainedEarningsMember2024-07-012024-09-300001379006nnvc:Dr.AnilDiwanMemberus-gaap:LineOfCreditMember2023-11-132023-11-130001379006srt:MinimumMembernnvc:Dr.AnilDiwanMember2026-03-312026-03-310001379006srt:MaximumMembernnvc:Dr.AnilDiwanMember2026-03-312026-03-310001379006srt:MinimumMembernnvc:Dr.AnilDiwanMember2025-07-012025-07-010001379006srt:MaximumMembernnvc:Dr.AnilDiwanMember2025-07-012025-07-010001379006srt:MinimumMembernnvc:Dr.AnilDiwanMember2024-09-232024-09-230001379006srt:MaximumMembernnvc:Dr.AnilDiwanMember2024-09-232024-09-230001379006srt:MinimumMembernnvc:Dr.AnilDiwanMember2024-09-230001379006srt:MaximumMembernnvc:Dr.AnilDiwanMember2024-09-230001379006us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:SeriesAPreferredStockMember2026-01-012026-03-310001379006us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:SeriesAPreferredStockMember2025-07-012026-03-310001379006nnvc:FounderChairmanAndPresidentMemberus-gaap:SeriesAPreferredStockMember2025-07-010001379006nnvc:PreFundedWarrantsMember2025-11-250001379006us-gaap:WarrantMember2026-02-280001379006us-gaap:WarrantMember2025-11-300001379006nnvc:SeriesWarrantsMemberus-gaap:PrivatePlacementMember2025-11-110001379006nnvc:SeriesBWarrantsMemberus-gaap:PrivatePlacementMember2025-11-110001379006nnvc:SeriesWarrantsMemberus-gaap:PrivatePlacementMember2025-11-100001379006nnvc:SeriesBWarrantsMemberus-gaap:PrivatePlacementMember2025-11-100001379006us-gaap:WarrantMember2025-08-3100013790062025-03-3100013790062024-06-300001379006nnvc:WarrantsExcludingParticipatingWarrantsMember2026-01-012026-03-310001379006nnvc:ParticipatingWarrantsMember2026-01-012026-03-310001379006nnvc:WarrantsExcludingParticipatingWarrantsMember2025-07-012026-03-310001379006nnvc:ParticipatingWarrantsMember2025-07-012026-03-310001379006nnvc:WarrantsExcludingParticipatingWarrantsMember2025-01-012025-03-310001379006nnvc:WarrantsExcludingParticipatingWarrantsMember2024-07-012025-03-310001379006us-gaap:WarrantMember2026-01-012026-03-310001379006us-gaap:WarrantMember2025-07-012026-03-310001379006nnvc:TheracourPharmaIncMemberus-gaap:RelatedPartyMember2026-03-310001379006nnvc:KarveerMeditechPvt.LtdMemberus-gaap:RelatedPartyMember2026-03-310001379006us-gaap:RelatedPartyMember2026-03-310001379006us-gaap:NonrelatedPartyMember2026-03-310001379006nnvc:TheracourPharmaIncMemberus-gaap:RelatedPartyMember2025-06-300001379006nnvc:KarveerMeditechPvt.LtdMemberus-gaap:RelatedPartyMember2025-06-300001379006us-gaap:RelatedPartyMember2025-06-300001379006us-gaap:NonrelatedPartyMember2025-06-3000013790062025-11-300001379006nnvc:June302031Member2025-07-012026-03-310001379006nnvc:June302030Member2025-07-012026-03-310001379006nnvc:June302029Member2025-07-012026-03-310001379006nnvc:June302028Member2025-07-012026-03-310001379006nnvc:June302027Member2025-07-012026-03-310001379006nnvc:June302026Member2025-07-012026-03-310001379006nnvc:PreFundedWarrantsMember2025-11-252025-11-250001379006us-gaap:CommonStockMember2026-01-012026-03-310001379006us-gaap:CommonStockMember2025-10-012025-12-310001379006us-gaap:CommonStockMember2025-07-012025-09-300001379006us-gaap:CommonStockMember2025-01-012025-03-310001379006us-gaap:CommonStockMember2024-10-012024-12-310001379006us-gaap:CommonStockMember2024-07-012024-09-300001379006nnvc:StockWarrantsMember2025-07-012026-03-310001379006nnvc:FounderChairmanAndPresidentMemberus-gaap:SeriesAPreferredStockMember2025-07-012025-07-010001379006nnvc:FounderChairmanAndPresidentMemberus-gaap:SeriesAPreferredStockMember2025-07-010001379006srt:ChiefFinancialOfficerMember2025-07-012025-07-010001379006nnvc:FounderChairmanAndPresidentMember2025-07-012025-07-010001379006nnvc:FounderChairmanAndPresidentMember2025-07-012025-07-010001379006us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001379006us-gaap:AdditionalPaidInCapitalMember2025-10-012025-12-3100013790062025-10-012025-12-310001379006us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-3000013790062025-07-012025-09-300001379006us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-3100013790062025-01-012025-03-310001379006us-gaap:AdditionalPaidInCapitalMember2024-10-012024-12-3100013790062024-10-012024-12-310001379006us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-3000013790062024-07-012024-09-300001379006nnvc:SeriesAConvertiblePreferredStockMember2026-01-012026-03-310001379006nnvc:SeriesAConvertiblePreferredStockMember2025-10-012025-12-310001379006nnvc:SeriesAConvertiblePreferredStockMember2025-07-012025-09-300001379006nnvc:SeriesAConvertiblePreferredStockMember2025-01-012025-03-310001379006nnvc:SeriesAConvertiblePreferredStockMember2024-10-012024-12-310001379006nnvc:SeriesAConvertiblePreferredStockMember2024-07-012024-09-300001379006nnvc:AtmOfferingMember2024-04-150001379006nnvc:SeriesWarrantsMemberus-gaap:PrivatePlacementMember2025-11-102025-11-100001379006nnvc:SeriesBWarrantsMemberus-gaap:PrivatePlacementMember2025-11-102025-11-100001379006nnvc:TheracourPharmaIncMemberus-gaap:RelatedPartyMember2019-11-012019-11-010001379006nnvc:KarveerMeditechPvt.LtdMemberus-gaap:RelatedPartyMember2023-03-272023-03-270001379006nnvc:SeriesAConvertiblePreferredStockMember2025-07-012026-03-3100013790062026-03-3100013790062025-06-300001379006us-gaap:CommonStockMember2025-11-100001379006nnvc:KarveerMeditechPvt.LtdMemberus-gaap:RelatedPartyMember2023-03-270001379006nnvc:FounderChairmanAndPresidentMemberus-gaap:SeriesAPreferredStockMember2025-07-012026-03-310001379006nnvc:RegisteredDirectOfferingMember2025-11-102025-11-1000013790062024-07-012025-03-310001379006srt:DirectorMember2026-01-012026-03-310001379006nnvc:ConsultingServicesMember2026-01-012026-03-310001379006srt:DirectorMember2025-07-012026-03-310001379006nnvc:ConsultingServicesMember2025-07-012026-03-310001379006nnvc:PreFundedWarrantsMember2025-11-100001379006nnvc:KarveerMeditechPvt.LtdMemberus-gaap:RelatedPartyMember2024-07-012025-06-300001379006nnvc:TheracourPharmaIncMember2026-03-310001379006nnvc:TheracourPharmaIncMember2025-06-3000013790062026-01-012026-03-3100013790062026-05-1400013790062025-07-012026-03-31xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesnnvc:itemxbrli:purennvc:segment\n\n[Table of Contents](#TOC)\n\n​\n\n​\n\n**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n**FORM ****10-Q**\n\n**QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF**\n\n**THE SECURITIES EXCHANGE ACT OF 1934.**\n\n**For the quarterly period ended****March 31, 2026**\n\n*Commission File Number:*001-36081\n\n**NANOVIRICIDES, INC.**\n\n*(Exact name of Company as specified in its charter)*\n\n​\n\nDelaware\n\n  ​ ​ ​\n\n76-0674577\n\n(State or other jurisdiction)\n\n \n\n(IRS Employer Identification No.)\n\nof incorporation or organization)\n\n \n\n \n\n​\n\n**1 Controls Drive**\n\n**Shelton****,****Connecticut********06484**\n\n(Address of principal executive offices and zip code)\n\n(203) 937-6137\n\n(*Company’s telephone number, including area code)*\n\nIndicate by check mark whether the Company (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Company was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ☒    No  ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  ☒    No  ☐\n\nIndicate by check mark whether the Company is a larger accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n​\n\nLarge accelerated filer\n\n☐\n\n \n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\n \n\nSmaller reporting company\n\n☒\n\n \n\n​\n\nEmerging growth company\n\n☐\n\n​\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the Company is a shell company (as defined in Rule 12b-2 of the Exchange Act).\n\nYes  ☐    No  ☒\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n​\n\n**Title of each class:**\n\n**  ​ ​ ​**\n\n**Trading Symbol(s)**\n\n**  ​ ​ ​**\n\n**Name of each exchange on which registered:**\n\nCommon Stock\n\n​\n\nNNVC\n\n​\n\nNYSE-American\n\n​\n\nAs of May 14, 2026 there were approximately 21,647,000 shares of common stock of the registrant issued and outstanding.\n\n​\n\n​\n\n​\n\n​\n\n[Table of Contents](#TOC)\n\nNanoViricides, Inc. \n\nFORM 10-Q \n\nINDEX\n\n​\n\n​\n\n[PART I FINANCIAL INFORMATION](#PARTIFINANCIALINFORMATION_167012)\n\n3\n\n​\n\n​\n\n[Item 1. Financial Statements](#Item1FinancialStatements_933056)\n\n3\n\n​\n\n​\n\n[Condensed Balance Sheets at March 31, 2026 (Unaudited) and June 30, 2025](#BalanceSheets_526038)\n\n3\n\n​\n\n​\n\n[Condensed Statements of Operations for the Three and Nine Months Ended March 31, 2026 and 2025 (Unaudited)](#StatementsofOperations_748311)\n\n4\n\n​\n\n​\n\n[Condensed Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended March 31, 2026 and 2025 (Unaudited)](#StatementofChangesinStockholdersEquity_6)\n\n5\n\n​\n\n​\n\n[Condensed Statements of Cash Flows for the Nine Months Ended March 31, 2026 and 2025 (Unaudited)](#StatementsofCashFlows_158932)\n\n7\n\n​\n\n​\n\n[Notes to the Condensed Financial Statements (Unaudited)](#NOTESTOTHEFINANCIALSTATEMENTS_620077)\n\n8\n\n​\n\n​\n\n[Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysisofF)\n\n18\n\n​\n\n​\n\n[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR)\n\n52\n\n​\n\n​\n\n[Item 4. Controls and Procedures](#ITEM4CONTROLSANDPROCEDURES_60231)\n\n52\n\n​\n\n​\n\n[PART II OTHER INFORMATION](#PARTIIOTHERINFORMATION_989368)\n\n53\n\n​\n\n​\n\n[Item 1. Legal Proceedings](#ITEM1LEGALPROCEEDINGS_450039)\n\n53\n\n​\n\n​\n\n[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES)\n\n53\n\n​\n\n​\n\n[Item 3. Defaults Upon Senior Securities](#ITEM3DEFAULTSUPONSENIORSECURITIES_963155)\n\n53\n\n​\n\n​\n\n[Item 4. Mine Safety Disclosures](#ITEM4MINESAFETYDISCLOSURES_813135)\n\n53\n\n​\n\n​\n\n[Item 5. Other Information](#ITEM5OTHERINFORMATION_244915)\n\n54\n\n​\n\n​\n\n[Item 6. Exhibits and Reports on Form 8-K](#ITEM6EXHIBITS_572989)\n\n55\n\n​\n\n​\n\n[Signatures](#SIGNATURES_591301)\n\n56\n\n​\n\n​\n\nCertifications\n\n​\n\n​\n\n​\n\n​\n\n2\n\n[Table of Contents](#TOC)\n\nPART I. FINANCIAL INFORMATION"}